P2RX4 P2X4 antibody Ab host: Goat
- Known as:
- P2RX4 P2X4 (anti-) Antibody production species: Goat
- Catalog number:
- 'AP31932PU-N
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- ACR
- Gene target:
- P2RX4 P2X4 antibody host: Goat
Related genes to: P2RX4 P2X4 antibody Ab host: Goat
- Gene:
- P2RX4 NIH gene
- Name:
- purinergic receptor P2X 4
- Previous symbol:
- -
- Synonyms:
- P2X4
- Chromosome:
- 12q24.31
- Locus Type:
- gene with protein product
- Date approved:
- 1997-10-09
- Date modifiied:
- 2016-10-05
- Gene:
- PPP1R18 NIH gene
- Name:
- protein phosphatase 1 regulatory subunit 18
- Previous symbol:
- KIAA1949
- Synonyms:
- phostensin
- Chromosome:
- 6p21.33
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-02
- Date modifiied:
- 2016-10-05
Related products to: P2RX4 P2X4 antibody Ab host: Goat
Related articles to: P2RX4 P2X4 antibody Ab host: Goat
- Recently, we suggested the combination of chemotherapy and P2RX4 inhibition as a promising novel therapeutic approach for P2RX4-expressing epithelial tumors to prevent paracrine resistance. Here, we aimed to assess whether determining P2RX4 expression status in colorectal and pancreatic cancer patients would allow stratification of potentially responsive patients. Therefore, P2RX4 expression levels were determined by RNA sequencing and immunohistochemistry. Subcellular localization of P2RX4 isoforms was analyzed in HeLa cells and patient-derived tumor organoids. In contrast to its RNA expression profile, P2RX4 protein levels exhibited differential regulation in human colorectal and pancreatic cancer epithelia due to alternative splicing. Interpatient heterogeneity was greater in colorectal cancer than in pancreatic cancer. Notably, these variations in expression did not correlate with overall patient survival. Alternative P2RX4 transcripts gave rise to functionally distinct protein isoforms that differed in subcellular localization and total protein abundance. Only the correctly spliced, canonical P2RX4 isoform was localized to the plasma membrane and was capable of mediating downstream signaling. Accordingly, P2RX4 inhibition in combination with chemotherapy was effective exclusively in patient-derived tumor organoids expressing the canonical P2RX4 transcript. In summary, immunohistochemical, but not transcriptomic, assessment of P2RX4 expression enabled the prediction of sensitivity to combinatorial treatment and facilitated the identification of patients who may benefit from P2RX4 inhibition during chemotherapy. Given the lower degree of heterogeneity observed in pancreatic cancer, this tumor entity may represent a promising candidate for early-phase clinical evaluation of chemotherapy combined with P2RX4 inhibition. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. - Source: PubMed
Publication date: 2026/06/03
Steup ChristophDosch JulianDietz-Fricke ChristopherKhosraviseftejani SaraEngel EstherValk Adalbert F deMenger DominicWelker PatrickWild Peter JKennel Kilian BKantlehner MajaZiegler Paul KGreten Florian R - The objectives of this study were to develop a real-world-data (RWD) database for patients with epilepsy to provide further real-world-evidence (RWE) for monogenic genetic epilepsies; to assess the usefulness of a diagnostic algorithm in epilepsy; and to examine protein 3D structures using in silico tools to predict variant pathogenicity. - Source: PubMed
Publication date: 2026/06/01
Morris HaleyMathew ElizabethBahl ShaliniVilla-Lopez MartaMercimek-Andrews Saadet - The P2RX7 gene has been linked to various neuropsychiatric disorders. In particular, the SNP rs2230912, which results in a glutamine-to-arginine substitution at position 460, has repeatedly been associated with mood disorders. Although this SNP per se does not affect receptor function, it tags a gain-of-function haplotype that has been shown to significantly enhance receptor activity. BAC-transgenic P2X7-reporter mice have proven to be valuable tools for monitoring P2X7 expression. Here, we exploited their capacity to simultaneously overexpress the receptor, thereby serving as gain-of-function models to assess the behavioral consequences of elevated P2X7 levels. We used the two currently available transgenic P2X7 reporter lines (sEGFP and P2X7-EGFP), which differ in their expression pattern, degree of overexpression, and co-expression of the neighbouring P2rx4 gene. Male sEGFP and P2X7-EGFP mice showed no alterations in general activity or in measures of anxiety-related or stress-coping behavior compared to their wild-type littermates. Only male P2X7-EGFP mice exhibited slightly delayed locomotor habituation to a novel environment. To what extent higher expression levels reflect enhanced receptor activity, as conveyed by the disease-associated gain-of-function haplotype, requires further investigation. Overall, these results indicate that P2X7 overexpression-whether at endogenous or ectopic sites, or in conjunction with P2X4-is not sufficient to substantially alter behavior of individually housed male mice under baseline conditions. - Source: PubMed
Publication date: 2026/05/09
Urbina-Treviño LidiaTang Haovon Mücke-Heim Iven-AlexEngel TobiasNicke AnnetteDeussing Jan M - P2 purinergic receptors are activated by extracellular adenosine triphosphate and other nucleotides released during inflammatory processes, cellular stress responses, and amplification by NETosis, thereby serving as pivotal mediators of both innate and adaptive immunity. In patients with active systemic lupus erythematosus (SLE), emerging evidence highlights the critical roles of distinct P2 receptors: P2RX4 and P2RY11 in initiating the immune response; P2RY2 in orchestrating immune cell recruitment; P2RX7 in promoting pro-inflammatory states coupled with impaired regulatory mechanisms; and P2RY12 as a driver of type I interferon signaling. Therapeutic targeting of these receptors through selective antagonists has demonstrated efficacy in preclinical lupus-prone models to restore regulatory functions (P2RX7), to control inflammation (P2RX7), type I interferon pathway (P2RY12), autoantibody production (P2RX4 and P2RX7), and glomerulonephritis (P2RX4, P2RX7, P2RY2, and P2RY12). In SLE, selective P2 antagonists are under investigation with major challenges regarding cellular specificity, therapeutic efficacy, and side effects. - Source: PubMed
Publication date: 2026/03/12
Renaudineau YvesBrooks Wesley - Early detection of hepatocellular carcinoma (HCC) remains a persistent worldwide challenge. Owing to its minimal invasiveness, liquid biopsy has emerged as a promising alternative for early screening. As key components of the tumor microenvironment (TME), platelets (PLTs) represent a rich source of biomolecular information that complements the data from conventional plasma and serum samples. Integrative multiomics analysis of such data offers a powerful strategy to deepen our understanding of hepatocarcinogenesis and accelerate the discovery of robust biomarker panels. Here, we described an integrative and ultrafast multiomics sample preparation (IAU-MOSP) strategy for the high-purity platelets. The optimized IAU-MOSP method shortened the multiomics workflow from over 24 to 6 h while yielding comparable biomolecule identifications to those of conventional methods. Then, the workflow was applied in an HCC cohort ( = 68) study. We quantified 6660 biomolecules with high reproducibility (median CVs: 0.31-0.39). The data exhibited strong cross-omics correlations, particularly between proteins and lipids ( = 0.75) as well as protein and metabolite ( = 0.68) groups. Differential analysis revealed 10 biomolecules significantly dysregulated in HCC platelets (TEK, citric acid, glycerol-3-phosphate (G3P), P2RX4, malic acid, ATP, PRG3, ITGAM, CXCR2, ITGB2) that participate in key pathways driving proliferation and metastasis. Accompanied by machine learning, the 10 biomolecules were ultimately identified as a potential biomarker panel for early diagnosis of HCC. It shows superior diagnostic efficacy (accuracy = 0.81, sensitivity = 0.74) over α-fetoprotein (AFP) (accuracy = 0.75, sensitivity = 0.45) for early HCC detection. - Source: PubMed
Publication date: 2026/03/10
Shen FenglinLiu YangRuan XuelianYan GuoquanZhang LeiFang JingLu HaojieHu ZuojianZhou Xinwen